GREEN MOUNTAIN ANTIBODIES, INC.

GREEN MOUNTAIN ANTIBODIES INC specializes in the research, development, and manufacturing of monoclonal and polyclonal antibodies targeting high-priority bacterial pathogens, with a demonstrated focus on ESKAPE pathogens—multidrug-resistant organisms that pose critical threats to military and public health. The company leverages advanced immunological techniques to engineer high-affinity, pathogen-specific antibodies for therapeutic and prophylactic applications, integrating molecular cloning, hybridoma technology, and recombinant expression systems. Their technical expertise lies in antigen design, epitope mapping, and scalable bioprocessing under GMP-aligned protocols, enabling the transition from discovery to preclinical-grade biological product manufacturing. A key differentiator is their targeted approach to antimicrobial resistance, positioning them as a niche developer of next-generation biologics for infectious disease countermeasures. The contractor has delivered specialized antibody development services to the Department of Defense, primarily supporting defense health initiatives aimed at mitigating battlefield-acquired infections and biothreat agents. This relationship reflects a focused engagement in military biomedical R&D, where rapid-response biologics development is critical to force protection and medical readiness. The company operates under NAICS 325414, which encompasses the manufacturing of biological products excluding diagnostics—specifically, therapeutic antibodies produced for clinical use. This places them squarely in the biopharmaceutical manufacturing sector, with a vertical specialization in anti-infective biologics and immunotherapeutics for defense and public health applications. GREEN MOUNTAIN ANTIBODIES INC is a small business structured as a 2L entity, headquartered in Burlington, Vermont. While currently holding no formal government certifications, their technical capabilities align with federal requirements for biological product development, and their geographic presence supports collaboration with regional academic and defense research institutions. Their market positioning is defined by precision antibody engineering for high-consequence pathogens, serving a specialized segment within the national security biodefense ecosystem.